bullish outlook rais pt
abbott report strong result initi guidanc wednesday morn
sale report pf stj came
consensu back strong perform medic devic epd
diagnost ep beat penni
lower interest expens off-set softer gross margin
higher sg back better expect quarter
abbott provid first-tim ep guidanc
bracket street estim expect
go releas coupl better expect
revenu guidanc organ well rang reflect street
big top-lin beat bullish guidanc outlin januari
upgrad street forecast view under-model abbott growth
potenti easi comparison key product
launch diabet electrophysiolog diagnost heart failur
manag guid busi mid- high-single-digit growth medic
devic sale low-single-digit growth nutrit sale
mid- high-single-digit growth diagnost ex-aler sale high-
single-digit growth establish sale
commentari key product launcheslibr allin confirmwa
bullish libr huge intern grow sequenti
yoy call manag endors prior year one commentari
libr us model includ today manag
also endors year sale confirm think conserv
comment come confer strong initi launch
tax reform tailwind talk note come
healthcar confer tax reform lower abbott effect tax rate
vs consensu enabl abbott
repatri previous trap cash give compani access
on-going basi global cash flow abbott go use cash acceler
pay-down deal-rel debt debt alreadi repaid earlier
januari make interest expens guidanc
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
compani ep guidanc bracket street consensu
expect go releas
moreov guidanc look conserv multipl lever even
abbott look reinvest tax top-lin driven upsid
mind updat estim rais dec price
target model sale report
organ factor fx tailwind sale aler
bottom line model cash ep reflect benefit
fx improv gm off-set increas sg
respect new price target valu share cash ep
premium large-cap peer current trade warrant given
compani top- bottom-lin growth outlook
invest thesi valuat risk
outlook look even better expect upon enter year
fundament abbott remain solid end market perform well organ
growth expect reach high end organ growth back
multipl new product launch includ us launch freestyl
libr glucos monitor system alin famili next-gener core lab
system heartmat left ventricular assist system confirm rx
implant cardiac monitor icm compet mdt linq mri
compat icd crt-d close competit gap strong
top line year deal accret st jude plu year aler turn
organ sale growth ep growth reinvest
even room upsid come compani abil access ou
cash post tax reform accret debt paydown
backdrop reiter overweight rate abbott
dec price target valu share ep
ebitda modest premium vs peer trade today
ep ebitda feel appropri given abbott top-
bottom-lin growth outlook upsid potenti see street estim
come year
risk rate price
downsid risk rate includ abbott macro exposur emerg
market poor integr failur stabil aler busi
potenti pipelin new product launch disappoint
abbott laboratori summari financi
cash equival
flow oper activ
o/w chang work capit
flow invest activ
sale
flow financ activ
net chang cash
adj free cash flow firm
compani report morgan estim
note million except per-shar data fiscal year end dec o/w
analyst certif research analyst denot ac cover report certifi multipl research
analyst primarili respons report research analyst denot ac cover within document
individu certifi respect secur issuer research analyst cover research view
express report accur reflect person view subject secur issuer part
research analyst compens directli indirectli relat specif recommend view
express research analyst report korea-bas research analyst list front cover also certifi per
kofia requir analysi made good faith view reflect opinion without undu influenc
